CTMX Q4 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+43.2% YoY

Gross Profit

$38M100.0% margin

Operating Income

$18M46.4% margin

Net Income

$19M49.6% margin

EPS (Diluted)

$0.24

QoQ Revenue Growth

+13.9%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$121M

Total Liabilities

$121M

Stockholders' Equity

-$456,000

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$27M	+43.2%
Gross Profit	$38M	$27M	+43.2%
Operating Income	$18M	-$606,000	+3017.3%
Net Income	$19M	$837,000	+2155.2%